Clinical Trial Update: Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

View source ↗

Summary

A clinical trial is evaluating glypican-3 as a prognostic factor in hepatocellular carcinoma patients treated with immunotherapy and is currently recruiting. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hepatocellular Carcinoma | Status: RECRUITING